Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Osiris Therapeutics, Inc. (OSIR): Are Hedge Funds Right About This Stock?

Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a greater amount of their resources in small-cap stocks than big brokerage houses, and this is often where they generate their outperformance, which is why we pay particular attention to their best ideas in this space.

Most Affordable Medical Schools in Europe

Osiris Therapeutics, Inc. (NASDAQ:OSIR) investors should pay attention to a decrease in hedge fund sentiment of late, with the number of bullish bets on the stock falling by one. At the end of this article we will also compare Osiris Therapeutics, Inc. (NASDAQ:OSIR) to other stocks including Blackstone / GSO Strategic Credit Fund (NYSE:BGB), Foundation Medicine Inc (NASDAQ:FMI), and Quidel Corporation (NASDAQ:QDEL) to get a better sense of its popularity.

Follow Osiris Therapeutics Inc. (NASDAQ:OSIR)
Trade (NASDAQ:OSIR) Now!

According to most investors, hedge funds are perceived as worthless, old investment tools of yesteryear. While there are more than 8,000 funds in operation today, experts at hedge fund tracking site Insider Monkey look at the bigwigs of this group, around 700 funds. Most estimates calculate that this group of people oversee the lion’s share of the hedge fund industry’s total asset base, and by shadowing their best stock picks, Insider Monkey has revealed numerous investment strategies that have historically outperformed Mr. Market. Insider Monkey’s small-cap hedge fund strategy defeated the S&P 500 index by 12 percentage points per annum for a decade in its back tests.

Now, we’re going to take a gander at the key action regarding Osiris Therapeutics, Inc. (NASDAQ:OSIR).

What have hedge funds been doing with Osiris Therapeutics, Inc. (NASDAQ:OSIR)?

At the end of the third quarter, a total of 10 of the hedge funds tracked by Insider Monkey held long positions in this stock, a drop of 9% from the previous quarter. With the smart money’s capital changing hands, there exists an “upper tier” of notable hedge fund managers who were boosting their stakes meaningfully.

According to Insider Monkey’s hedge fund database, Mitchell Blutt’s Consonance Capital Management has the biggest position in Osiris Therapeutics, Inc. (NASDAQ:OSIR), worth close to $37.6 million, corresponding to 5.3% of its total 13F portfolio. The second-largest stake is held by Baker Bros. Advisors, led by Julian Baker and Felix Baker, holding a $9.2 million position; 0.1% of its 13F portfolio is allocated to the stock. Other hedgies with similar optimism contain Jim Simons’ Renaissance Technologies, Jeffrey Jay and David Kroin’s Great Point Partners, and D E Shaw.

Since Osiris Therapeutics, Inc. (NASDAQ:OSIR) has experienced declining sentiment from the smart money, logic holds that there lies a certain “tier” of money managers that slashed their entire stakes by the end of the third quarter. At the top of the heap, Brandon Osten’s Venator Capital Management cut the biggest investment of all the hedgies followed by Insider Monkey, totaling an estimated $4.2 million in stock, while Peter Rathjens, Bruce Clarke and John Campbell of Arrowstreet Capital were right behind this move, dropping about $0.9 million worth of shares. These moves are intriguing to say the least, as total hedge fund interest fell by one fund at the end of the third quarter.

Let’s also examine hedge fund activity in other stocks similar to Osiris Therapeutics, Inc. (NASDAQ:OSIR). These stocks are Blackstone / GSO Strategic Credit Fund (NYSE:BGB), Foundation Medicine Inc (NASDAQ:FMI), Quidel Corporation (NASDAQ:QDEL), and Raven Industries, Inc. (NASDAQ:RAVN). This group of stocks’ market valuations match Osiris Therapeutics, Inc. (NASDAQ:OSIR)’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
BGB 7 50633 3
FMI 7 46856 0
QDEL 12 29063 -3
RAVN 9 46272 0

As you can see these stocks had an average of nine hedge funds with bullish positions and the average amount invested in these stocks was $43 million. Investments in Osiris were higher, with money managers that we track owning $53 million worth of its shares and 8.30% of its stock. Quidel Corporation (NASDAQ:QDEL) is the most popular stock in this table. On the other hand Blackstone / GSO Strategic Credit Fund (NYSE:BGB) is the least popular one with only seven bullish hedge fund positions. Osiris Therapeutics, Inc. (NASDAQ:OSIR) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. Given the declining interest in Osiris, it is not one of those stocks at this time.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!